Review article: Oral, modified-release mesalazine formulations - Proprietary versus generic

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 10, 2003, Pages 1207-1214

  Forbes, A ^a   Cartwright, A ^b   Marchant, S ^a   McIntyre, P ^c   Newton, M ^d  

^a ST MARK S HOSPITAL   (United Kingdom)

^b Global Regulatory Solutions Ltd   (United Kingdom)

^c QUEEN ELIZABETH II HOSPITAL   (United Kingdom)

^d Queen Elizabeth II Hospital ^*

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; MESALAZINE;

BIOEQUIVALENCE; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DRUG EFFICACY; DRUG SOLUBILITY; ENTERITIS; PATENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; CROHN DISEASE; DRUGS, GENERIC; HUMANS; INFLAMMATORY BOWEL DISEASES; MESALAMINE; THERAPEUTIC EQUIVALENCY;

EID: 0038620397     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01578.x     Document Type: Review

References (30)

1. Prakash A, Markham A. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease. Drugs 1999; 57(3): 383-408.
2. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977; 2(8044): 892-5.
3. Martin F. Oral 5-aminosalicylic acid preparations in treatment of inflammatory bowel disease. An update. Dig Dis Sci 1987; 32(12 Suppl.): 57S-63S.
4. Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993; 118(7): 540-9.
5. Kamm MA. Maintenance of remission in ulcerative colitis. Aliment Pharmacol Ther 2002; 16(Suppl. 4): 21-4.
6. Sutherland L, Roth D, Beck P, May G, Makiyama K. Oral 5-aminosalicylic acid for maintaining remission in ulcerative colitis. Cochrane Database Syst Rev 2000; 2: CD000544.
7. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347(6): 417-29.
8. British Medical Association and the Royal Pharmaceutical Society of Great Britain. Chronic bowel disorders. In: British National Formulary. No. 43. London: British Medical Association, 2002: 48-9.
9. Colorectal agents. In: Monthly Index of Medical Specialties. London: Haymarket Medical Publications, 2002: 22-5.
10. Forbes A. 5-Aminosalicylates in inflammatory bowel disease -the more the merrier? Eur J Gastroenterol Hepatol 1995; 7(11): 1017-9.
11. Forbes A, Chadwick C. Mesalazine preparations. Lancet 1997; 350(9087): 1329.
12. Haagen Nielsen O, Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal instillation in man. Br J Clin Pharmacol 1983; 16(6): 738-40.
13. Frieri G, Giacomelli R, Pimpo M, et al. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut 2000; 47(3): 410-4.
14. Farrell RJ, Peppercorn MA. Equimolar doses of balsalazide and mesalamine: are we comparing apples and oranges? Am J Gastroenterol 2002; 97: 1283-5.
15. Clemett D, Markham A. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease. Drugs 2000; 59(4): 929-56.
16. Gionchetti P, Amadini C, Rizzello F, Venturi A, Campieri M. Treatment of mild to moderate ulcerative colitis and pouchitis. Aliment Pharmacol Ther 2002; 16(Suppl. 4): 13-9.
17. Christensen LA, Fallingborg J, Abildgaard K, et al. Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. Aliment Pharmacol Ther 1990; 4(5): 523-33.
18. Staerk Laursen L, Stokholm M, Bukhave K, Rask-Madsen J, Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990; 31(11): 1271-6.
19. Forbes A. Inflammatory Bowel Disease: A Clinician's Guide. 2nd edn. London: Arnold/Hodder, 2001.
20. Directive 2002/83/EC of the European Parliament and of the Council. OJ 311/67 28.11.2001. Article 10(1)(a)(iii).
21. Judgement of the Court (Fifth Chamber) - December 1998, in case C-368/96, reference to the Court under Article 177 of the EC Treaty by the High Court of Justice (England and Wales), Queen's Bench Division, for a preliminary ruling in the proceedings pending between that Court between The Queen and The Licensing Authority established by the Medicines Act 1968 ex parte Generics (UK) Ltd, intervene E.R. Squibb Ltd etc. 1998.
22. Rules Governing Medicinal Products in the European Union. Notice to Applicants. Vol. 2A. 2001: Chapter 1 - Marketing Authorisations. http://www.emea.eu.int
23. National Prescribing Centre. Modified-release preparations. MeReC Bull 2000; 11: 13-6.
24. European Pharmacopoeia, 4.0. 2002. http://online.pheur.org
25. Podczeck F, Course NJ, Newton JM. Determination of the gastric emptying of solid dosage forms using gamma-scintigraphy: a problem of image timing and mathematical analysis. Eur J Nucl Med 1999; 26(4): 373-8.
26. Nugent SG, Kumar D, Rampton DS, Evans DF. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 2001; 48(4): 571-7.
27. Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 1988; 29(8): 1035-41.
28. Naganuma M, Iwao Y, Ogata H, et al. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine. Inflamm Bowel Dis 2001; 7(3): 221-5.
29. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. Br Med J 1996; 313(7048): 36-9.
30. Committee for Proprietary Medicinal Products. Points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome. CPMP/EWP/785/97. 2002. http://www.emea.eu.int